BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19204674)

  • 1. Avastin-Tarceva combination fails in lung cancer.
    Jones D
    Nat Biotechnol; 2009 Feb; 27(2):108-9. PubMed ID: 19204674
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy.
    Munoz J; Hong D; Kurzrock R
    Int J Hematol; 2012 Jan; 95(1):1-2. PubMed ID: 22170230
    [No Abstract]   [Full Text] [Related]  

  • 3. [Erlotinib. A new option for non-small cell lung cancer].
    Polk B
    Med Monatsschr Pharm; 2006 Jan; 29(1):4-6. PubMed ID: 16463547
    [No Abstract]   [Full Text] [Related]  

  • 4. Lung cancer: looking ahead in 2004.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role?
    Kalemkerian G
    J Clin Oncol; 2005 Feb; 23(6):1325-6; author reply 1326-7. PubMed ID: 15718337
    [No Abstract]   [Full Text] [Related]  

  • 6. [Targeted therapies for lung cancer].
    Tamura K
    Rinsho Ketsueki; 2008 Aug; 49(8):616-21. PubMed ID: 18800610
    [No Abstract]   [Full Text] [Related]  

  • 7. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 8. [Non-small cell lung cancer: 1) Molecular-target therapy].
    Muguruma H; Yano S; Sone S
    Nihon Naika Gakkai Zasshi; 2003 Jul; 92(7):1284-90. PubMed ID: 12924275
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer.
    Raez LE; Lopes G; Lilenbaum R
    J Clin Oncol; 2005 Jun; 23(18):4244-5. PubMed ID: 15961783
    [No Abstract]   [Full Text] [Related]  

  • 10. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.
    Rosell R
    J Clin Oncol; 2004 Apr; 22(7):1171-3. PubMed ID: 14981109
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Mar; 6(5):267-8. PubMed ID: 15845175
    [No Abstract]   [Full Text] [Related]  

  • 12. [Bevacizumab in the treatment of non-small cell lung cancer].
    Knuuttila A; Rouhos A; Karjalainen EM; Riska H; Pietiläinen M; Paunu N; Salomaa ER
    Duodecim; 2009; 125(4):361-8. PubMed ID: 19358416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
    Agus DB; Bunn PA; Franklin W; Garcia M; Ozols RF
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. PubMed ID: 11236029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research unveils the 'who' and 'why' of gefitinib.
    Vastag B
    J Natl Cancer Inst; 2004 Sep; 96(18):1352-4. PubMed ID: 15367564
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
    Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
    Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reporting of studies on new medicines in major medical journals: a case study in breast cancer.
    Vitry AI
    Clin Pharmacol Ther; 2010 Apr; 87(4):398-400. PubMed ID: 20305673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.